Corneal Transplant — Cost, Top Hospitals & Success Rates | MyMedicPlus

Corneal transplantation (keratoplasty) is a surgical procedure in which diseased or damaged corneal tissue is replaced with healthy donor corneal tissue to restore transparency and visual function. The cornea is the clear, dome-shaped front surface of the eye through which light passes; it provides approximately 70% of the eye's total refractive power. When the cornea becomes clouded, distorted, or thinned beyond functional correction, transplantation is the definitive treatment to restore sight.

Corneal grafting is the most commonly performed human tissue transplant worldwide, with approximately 185,000 procedures performed annually. Modern surgery has moved away from full-thickness corneal replacement (penetrating keratoplasty, PKP) towards component-selective lamellar transplantation, which replaces only the diseased layer of the cornea. This fundamental shift has dramatically improved visual outcomes, reduced rejection rates, and shortened recovery times. The three dominant lamellar techniques are Descemet's Membrane Endothelial Keratoplasty (DMEK — replacing only the innermost Descemet's membrane and endothelium), Descemet's Stripping Endothelial Keratoplasty (DSAEK — replacing the posterior stroma, Descemet's membrane, and endothelium), and Deep Anterior Lamellar Keratoplasty (DALK — replacing the anterior stroma for conditions affecting the front layers while preserving a healthy endothelium).

Donor corneas are obtained from eye banks, which process, test, and grade tissue from consented deceased donors. All donor tissue is screened for transmissible diseases. The Eye Bank Association of America and European Eye Bank Association maintain quality standards for tissue grading. Endothelial cell count of the donor tissue (healthy tissue: >2,000 cells/mm²) is a key quality parameter. In many countries, opt-out organ donation systems have increased corneal tissue availability.

Fuchs' endothelial corneal dystrophy is the most common indication for corneal transplantation in Western countries, accounting for approximately 30–40% of procedures. It is a progressive bilateral condition in which the corneal endothelial cells degenerate, impairing the pump function that keeps the cornea dehydrated and transparent. Initially causing glare and halos, it progresses to corneal oedema, blurred vision, and painful bullous keratopathy. DMEK and DSAEK are the procedures of choice for Fuchs' dystrophy, replacing only the diseased endothelial layer.

Keratoconus is a progressive ectatic condition in which the cornea thins and bulges into a cone shape, causing severe irregular astigmatism not correctable with spectacles. It is the most common indication for corneal transplantation in young patients and the most common indication globally. DALK is preferred for keratoconus when the endothelium is healthy, preserving the patient's own Descemet's membrane and endothelium and eliminating endothelial rejection risk. Corneal scarring from infections (herpes simplex keratitis, bacterial corneal ulcer, trachoma), chemical burns, and trauma; pseudophakic bullous keratopathy from surgical endothelial damage; and advanced lattice, granular, and macular dystrophies round out the major indications.

Candidates for corneal transplantation are patients with significant visual loss or intractable pain from corneal disease that cannot be managed adequately with non-surgical interventions. Specific eligibility depends on the underlying condition: for keratoconus, corneal collagen cross-linking (CXL) is attempted first to halt progression, and spectacle or contact lens correction provides acceptable vision until surgical thresholds are reached. Intolerance to rigid gas-permeable or scleral lens fitting, or best-corrected visual acuity below 6/36 despite optimal optical correction, typically drives referral for DALK.

For Fuchs' dystrophy, symptomatic corneal oedema causing visual acuity below 6/18 combined with a low endothelial cell count on specular microscopy triggers surgical discussion. The general health of the patient influences anaesthetic choices and surgical planning, but there is no upper age limit for corneal transplantation. A healthy posterior segment (retina, optic nerve, macula) is essential for a good visual outcome. Patients with severe dry eye, uncontrolled glaucoma, or active uveitis require management of these conditions before proceeding to corneal transplantation.

DMEK (Descemet's Membrane Endothelial Keratoplasty) is now the preferred technique for endothelial failure (Fuchs' dystrophy, pseudophakic bullous keratopathy). A very thin graft containing only Descemet's membrane and endothelium (approximately 10–15 micrometres) is inserted through a 3mm incision, unrolled inside the anterior chamber, and positioned against the recipient stroma with an air bubble injected to push it into position. DMEK achieves the fastest visual recovery (20/20–20/25 vision in 3–6 weeks in favourable cases) and has the lowest rejection rate (approximately 1%) of all transplant techniques due to the minimal amount of foreign donor tissue transplanted.

DSAEK (Descemet's Stripping Automated Endothelial Keratoplasty) uses a thicker lenticule (~100–150 micrometres) including the posterior stroma, Descemet's membrane, and endothelium. It is technically less demanding than DMEK and is preferred for complex cases (prior filtering glaucoma surgery, iris abnormalities, vitrectomised eyes). Visual recovery is slightly slower (3–6 months to best vision) and rejection rates slightly higher than DMEK but lower than PKP. DALK (Deep Anterior Lamellar Keratoplasty) for keratoconus uses big-bubble technique or layer-by-layer dissection to remove the anterior stroma while preserving Descemet's membrane, then sutures a full anterior-stroma donor graft in place. Penetrating keratoplasty (PKP) — full-thickness corneal replacement secured with 16 interrupted or running nylon sutures — remains the procedure of choice for full-thickness opacification (chemical burns, herpes scars) and cases where all corneal layers are affected.

DMEK delivers the best visual outcomes in modern corneal surgery: large series report 70–80% of patients achieving 20/25 or better best-corrected visual acuity at one year, with minimal induced astigmatism (mean ~0.75 dioptres). The near-zero immune rejection rate with DMEK (approximately 1% compared to 10–15% for PKP) means patients require minimal long-term topical steroid use, reducing steroid-related complications such as cataract and glaucoma. Graft survival at 5 years exceeds 90% in both DMEK and DSAEK.

For keratoconus treated with DALK, rejection of the donor tissue does not occur (as the endothelium is not transplanted), so the primary risk of immune rejection is eliminated. DALK achieves best-corrected visual acuities of 20/30–20/40 or better in 60–80% of cases, with spectacle or rigid contact lens correction of residual irregular astigmatism often achieving 20/20. For patients with PKP for corneal scarring or complex dystrophies, visual improvement is significant though recovery is prolonged (12–18 months for suture removal), and best vision requires management of high post-PKP astigmatism through selective suture removal, arcuate keratotomy, or laser vision correction after the graft is stable.

Immune rejection is the most feared complication of corneal transplantation. Symptoms — reduced vision, photophobia, redness, and pain — must be recognised early and treated aggressively with intensive topical steroids. PKP carries the highest rejection risk (10–15% at 5 years); DSAEK 3–5%; DMEK approximately 1%. Endothelial cell loss is an ongoing process after all corneal transplants, and when the endothelial cell count falls below a functional threshold, the graft fails and may require regrafting. Primary graft failure (immediate non-function of the donor endothelium) occurs in 1–5% of cases.

DMEK-specific complications include graft detachment (requiring a second air bubble injection — rebubbling — in 10–15% of cases) and graft upside-down insertion. DALK-specific complications include Descemet's membrane perforation during deep dissection, converting the procedure to PKP. Infection (bacterial keratitis, fungal keratitis, herpes simplex reactivation) is a serious late complication requiring prompt treatment. Suture-related complications in PKP include suture infection, suture loosening causing high astigmatism, and neovascularisation along suture tracks. Glaucoma may develop as a late complication particularly after PKP.

Post-operative management after DMEK or DSAEK involves face-up positioning for the first 24–48 hours to allow the air bubble to support graft adhesion. Topical steroid drops (prednisolone acetate 1%) are used intensively: every 2 hours for 2 weeks, tapering gradually over 12 months for DMEK (indefinite low-dose steroids long-term reduce rejection risk). Topical antibiotic drops are used for 4 weeks. Follow-up visits at day 1, week 1, month 1, 3 and 6 months, and annually thereafter assess graft clarity, best-corrected visual acuity, intraocular pressure, and endothelial cell count by specular microscopy.

After PKP, sutures are typically removed selectively from 6 months post-operatively based on refraction, topography, and loose suture detection. Full visual rehabilitation may take 12–24 months. Patients receive a steroid taper over 12–18 months and must recognise rejection symptoms (RSVP: Redness, Sensitivity to light, Vision reduction, Pain) and attend for emergency treatment within 24 hours of symptom onset. Wearing protective glasses and avoiding eye trauma is important for life, as the transplanted graft is mechanically vulnerable to traumatic rupture along the scar.

Corneal transplantation in the United States costs USD 13,000–25,000 per eye when including surgeon fees, anaesthesia, facility charges, and donor tissue fees. The Eye Bank tissue fee alone is USD 2,000–4,000. In the UK, NHS corneal transplantation is available free of charge for eligible patients; private surgical costs are GBP 5,000–10,000 per eye. The procedure is performed in most major cities but waiting times for donor tissue and theatre availability can be 12–18 months.

Medical tourism for corneal transplantation is well-established in India, where world-class ophthalmology centres (Sankara Nethralaya Chennai, LV Prasad Eye Institute Hyderabad, Shroff Eye Hospital Delhi) perform DMEK, DSAEK, and DALK with internationally trained corneal surgeons at costs of USD 1,500–4,000 per eye all-inclusive. India has its own functioning eye bank network with quality-graded donor tissue. Thailand (Rutnin Eye Hospital) and Singapore (Singapore National Eye Centre) offer DMEK and DSAEK at USD 3,000–7,000. Post-operative follow-up care is extensive; medical tourists typically plan a 2-week stay for DMEK/DSAEK and 3–4 weeks for PKP with multiple post-operative checks.

For early Fuchs' dystrophy causing mild blurring and glare, topical 5% sodium chloride (hypertonic saline) drops reduce corneal oedema temporarily and may delay the need for surgery by months to years. A hair dryer held at arm's length to dry the corneal surface on waking is a traditional but symptom-managing manoeuvre that exploits the fact that corneal oedema is worst after eye closure during sleep. For keratoconus, corneal collagen cross-linking (CXL) halts disease progression in 95% of cases and should be performed as soon as progressive keratoconus is confirmed in younger patients, preventing the need for transplantation.

Scleral contact lenses and mini-scleral lenses provide excellent visual rehabilitation for advanced keratoconus and irregular corneas without surgery, with best-corrected visual acuities approaching 20/20 in many cases, making them a viable long-term alternative to DALK for patients who can tolerate lens wear. Phakic IOL implantation and refractive surgery (topography-guided PRK) are not appropriate treatments for keratoconus or Fuchs' dystrophy. Artificial corneas (Boston KPro, osteo-odonto keratoprosthesis) are reserved as last resort for repeatedly rejected grafts or severely vascularised corneas where conventional transplantation has a very poor prognosis.